62868-79-5
Chemical Structure
2,3-Diphosphoglyceric acid (pentacyclohexylamine)
Synonym(s): 2,3-DPG (pentacyclohexylamine)
- CAS No.: 62868-79-5
- Formula:C33H73N5O10P2
- Molecular Weight:761.91
InChIKey: WMBJYTVZNODJKS-UHFFFAOYSA-N
SMILES: NC1CCCCC1.O=C(C(COP(O)(O)=O)OP(O)(O)=O)O.NC2CCCCC2.NC3CCCCC3.NC4CCCCC4.NC5CCCCC5
Biological Activity: 2,3-Diphosphoglyceric acid (2,3-DPG) pentacyclohexylamine is an intermediate metabolite of the 2,3-BPG shunt in erythrocytes, capable of binding to hemoglobin and modulating oxygen affinity. 2,3-Diphosphoglyceric acid pentacyclohexylamine stabilizes the deoxyhemoglobin T-state conformation, reduces hemoglobin oxygen affinity, and promotes oxygen release in tissues. 2,3-Diphosphoglyceric acid pentacyclohexylamine inhibits the growth of Plasmodium falciparum within erythrocytes without causing hemolysis or a decrease in ATP levels. 2,3-Diphosphoglyceric acid pentacyclohexylamine is useful for research related to malaria and Alzheimer's disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2,3-Diphosphoglyceric acid (pentacyclohexylamine) | 2,3-Diphosphoglyceric acid (2,3-DPG) pentacyclohexylamine is an intermediate metabolite of the 2,3-BPG shunt in erythrocytes, capable of binding to hemoglobin and modulating oxygen affinity. 2,3-Diphosphoglyceric acid pentacyclohexylamine stabilizes the deoxyhemoglobin T-state conformation, reduces hemoglobin oxygen affinity, and promotes oxygen release in tissues. 2,3-Diphosphoglyceric acid pentacyclohexylamine inhibits the growth of Plasmodium falciparum within erythrocytes without causing hemolysis or a decrease in ATP levels. 2,3-Diphosphoglyceric acid pentacyclohexylamine is useful for research related to malaria and Alzheimer's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Płoszczyca K, et al. Red Blood Cell 2,3-Diphosphoglycerate Decreases in Response to a 30 km Time Trial Under Hypoxia in Cyclists. Frontiers in physiology. 2021;12:670977. [Content Brief]
- [2]. Morais I, et al. Synthetic Red Blood Cell-Specific Glycolytic Intermediate 2,3-Diphosphoglycerate (2,3-DPG) Inhibits Plasmodium falciparum Development In Vitro. Front Cell Infect Microbiol. 2022 Mar 15;12:840968. [Content Brief]
- [3]. Kosenko EA, et al. Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease. CNS & neurological disorders drug targets. 2016;15(1):113-23. [Content Brief]
